Image Source: Unsplash

Bristol-Myers Squibb Co (BMY) discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders.

A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development.

Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Three key data points gauge Bristol-Myers Squibb Co. or any dividend-paying firm.

The key three are:

(1) Price

(2) Dividends

(3) Returns

Those three basic keys best tell whether any company has made, is making, and will make money.

BMY Price

Over the past year, Bristol’s share price dropped about 20.3% from $71.21 to $56.73 as of Wednesday’s market close.

If BMY stock trades in the range of $50.00 to $75.00 this next year, its recent $56.73 share price might rise to $70.00 by next year. Of course, BMY’s price could drop about the same $13.27 estimated amount or more.

My upside estimate of $13.27, however, is about $2.39 under the median of one-year target prices estimated by 23 analysts covering BMY for brokers.

BMY Dividend

Bristol has paid regular Quarterly dividends since February 1, 1986.  BMY’s most recent Q dividend, payable November 1st to shareholders of record October 5th, is $0.57. The resulting $2.28 annual return casts a forward yield of 4.02% per Wednesday’s closing price.

BMY Returns

Add the $2.28 anticipated annual dividend to Bristol’s estimated $13.27 possible price upside, revealing a $15.55 potential gross gain per share for the coming year.

At Monday’s $56.72 closing price, a little over $1000 would buy 18 shares.

A $10 broker fee (if charged), paid half at purchase and half at sale, might cost us about $0.56 per share.

Subtracting that likely $0.56 brokerage cost from my estimated $15.55 gross gain per share makes a net gain of $14.99 X 18 shares = $269.82 or about a 26.5% net gain.

This might be nearly time to pounce on BMY shares. But beware, BMY is a U.S.  Pharmaceutical Company paying Annual dividends for thirty-seven years. However, the estimated $40.20 annual dividend from $1000 invested comes in at $16.52 short of equalling the recent $56.72 single share price. The choice is yours but waiting for Bristol’s price to drop below $47.75 is best for annual dividend returns from a $1k investment to equal the single share price.

Remember the true value of any stock is best realized through personal ownership of shares.

More By This Author:

Current Analysis: Orion Oyj
Current Analysis: LTC Properties
Current Analysis: Eisai (ESAIY)